镭-223用于转移性去势抵抗性前列腺癌：临床开发及在当代实践中的应用
Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
作者信息
Morgan Scott C
机构信息
Division of Radiation Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada.
出版信息
J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S26-S30. doi: 10.1016/j.jmir.2019.05.006. Epub 2019 Jun 21.
Radium-223 is a first-in-class alpha particle-emitting radionuclide. Unlike the beta emitters whose development preceded it and whose use has largely been limited to symptom palliation, radium-223 has been shown to meaningfully alter the natural history of bone-predominant metastatic castration-resistant prostate cancer and improve overall survival. This review-a précis of a lecture given at the Eleventh International Symposium on Targeted Alpha Therapy in April 2019-discusses the radiobiological properties of radium-223, summarizes its clinical development over the past decade, and situates it in the current therapeutic landscape for metastatic castration-resistant prostate cancer.
镭-223是首个发射α粒子的放射性核素。与在它之前研发且其用途主要限于缓解症状的β发射体不同，镭-223已被证明能显著改变以骨转移为主的去势抵抗性前列腺癌的自然病程并提高总生存期。这篇综述——2019年4月在第十一届靶向α治疗国际研讨会上所做讲座的摘要——讨论了镭-223的放射生物学特性，总结了其在过去十年的临床研发情况，并将其置于去势抵抗性前列腺癌的当前治疗格局中。
Zotero 插件